UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
$113.68
0.00%
(0.00) 1D
Oct 8, 3:59:58 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Mkt. cap
39.33B
Avg. vol.
48.44K
Volume
355.00
52-wk high
$168.76
52-wk low
$112.15
Beta
0.57
Shares outstanding
389.01M
No. of employees
9K
Mkt. cap
39.33B
Avg. vol.
48.44K
Volume
355.00
52-wk high
$168.76
52-wk low
$112.15
Beta
0.57
Shares outstanding
389.01M
No. of employees
9K
News stories
From web sources and news partners
AD HOC NEWS
·
1 hour ago
UCB presented EADV data and UCB stock trades 30.07 percent below its high
AD HOC NEWS
·
1 day ago
UCB stock loses 0.61 percent pre-market to EUR 202.30
AD HOC NEWS
·
2 days ago
UCB stock reports 22 percent H1 revenue growth
AD HOC NEWS
·
2 days ago
UCB stock carries first half drug sales into October
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com